Neurocrine Biosciences, Inc.
NASDAQ:NBIX 4:00:00 PM EDT
| Market Cap (Intraday) | 13.21B |
| Current PE | 43.20 |
| Forward PE | 34.31 |
| 2yr Forward PE | 22.59 |
| 10-Day MA | $131.73 |
| 50-Day MA | $124.70 |
| 200-Day MA | $122.02 |
Neurocrine Biosciences, Inc. Stock, NASDAQ:NBIX
6027 Edgewood Bend Court, San Diego, California 92130
United States of America
Phone: +1.858.617.7600
Number of Employees: 1800
Description
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.